Navigation Links
Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
Date:11/2/2010

progress with potential manufacturing partners for Phase 3.

In conjunction with the release of financial results for the third quarter ended September 30, 2010, Anthera will host a conference call at 5 pm Eastern Time, November 2, 2010. U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190. The conference ID is 19111226. To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291. The conference ID for the replay is 19111226. The audio replay will be available until November 9, 2010. This conference call will be webcast live and archived on Anthera's website until November 2, 2011, www.anthera.com.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, varespladib, and two Phase 2 clinical programs, A-623 and A-001. Varespladib and A-001 inhibit a novel enzyme target known as sPLA2 . Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or (BAFF), which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements made pursuant to the safe harbor pr
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
2. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
3. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
4. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
5. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
6. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
8. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
9. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
11. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)...  Aurobindo Pharma USA is ... mg 100-count bottles to the consumer level. The product ... Empty capsules could result in missed dose(s) ... range from no effect, short term reduction in efficacy, ... seizures) that could be life-threatening. Aurobindo Pharma ...
(Date:11/22/2014)... MIAMI , Nov. 22, 2014  New data ... for the most common form of female sexual dysfunction, ... cognitive function or driving performance in premenopausal women when ... Sexual Medicine Society of North America,s ... Miami . SMSNA accepted ...
(Date:11/22/2014)... noviembre de 2014  BioClinica®, Inc., un proveedor ... tecnologías eClinical, ha indicado un aumento de la ... el seguimiento basado en el riesgo en los ... del seguimiento basado en el riesgo más allá ... seguimiento o cambio de los métodos de seguimiento. ...
Breaking Medicine Technology:Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
... June 1, 2011 Esperance ... of a $7.5 million Series B financing. Proceeds from ... EP-100, the lead cancer-targeting drug candidate from Esperance,s Cationic ... of the Company,s pipeline. Sanofi led the Series B ...
... June 1, 2011 MMRGlobal, Inc. (OTCBB: ... www.deutsch-boerse.com ) have entered into an agreement ... health IT products and services, including MMRPro for healthcare ... Health Record (PHR) ( www.mmrvideos.com ), on the ...
Cached Medicine Technology:Esperance Pharmaceuticals Completes $7.5 Million Series B Financing 2VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 2VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 3VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 4VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 5
(Date:11/24/2014)... California (PRWEB) November 24, 2014 ... USD 6.19 billion by 2020, according to a ... incidence rates of cardiac arrhythmias clubbed with growing ... of this market. Though still in the budding ... significant rise in usage rates in the recent ...
(Date:11/24/2014)... CHICAGO (PRWEB) November 24, 2014 ... VolparaAnalytics version 1.2 at the 100th Annual Meeting ... November 30-December 5, 2014 (RSNA Booth 1752 – ... version of VolparaAnalytics and the rest of its ... VolparaDensity and VolparaDoseRT, which enable personalized measurements of ...
(Date:11/24/2014)... Virginia (PRWEB) November 24, 2014 Residents ... center stage in this year’s SENIORS GOT TALENT, an ... Guide. , From piano players to classic crooners, to ... clear that older adults are indeed living young. , ... competition because there’s a cash prize, has always been ...
(Date:11/24/2014)... Olaparib functions as a chemical of ... one of the first PARP inhibitors. Sufferers with BRCA1/2 ... of melanoma, and are often immune to other types ... malignancies a exclusive weaknesses, as the tissues of melanoma ... and allow them to proceed splitting. This implies that ...
(Date:11/24/2014)... York (PRWEB) November 24, 2014 The ... by the Family and Children's Association to ... as soap, shampoo, mouthwash and other such items.The Association's ... who are home bound, living in nursing homes, assisted ... to greatly enhance the well being of seniors throughout ...
Breaking Medicine News(10 mins):Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3
... the latest study by the Mayo clinic, injecting an anesthetic ... ,The new study that is being presented today ... the American Urological Association, in San Diego, had found that ... of pain during their biopsy. It was explained that the ...
... disease of the rich and comfortably off in India has now ... classes in India.// , The disease has become so ... with the diabetic population in the country reaching a count of ... to more than double. ,International attention has been drawn ...
... caused drastic increase in cancer among kids across Europe. They ... cases of cancer in kids identified between 1978 and 1997 ... to the results, there was an increase by an average ... in children under the age of 14. ,Majority ...
... According to a review that was published in the Friday’s issue ... reduce their risk of fractures in the later years.// ... got by the age of 18 years. Hence, it is expected ... effects of age-related bone loss and osteoporosis. ,The results ...
... used to treat migraine headaches can be effective in ... zolmitriptan targets nerves that carry pain signals, Dr. Peter ... said.// ,Cluster headaches are not as common as ... 92 patients with cluster headaches. In the final analysis ...
... wells near the Queen’s Balmoral Castle in Scotland kills cancer ... biochemistry at the University of Maribor in Slovenia said that ... and compared them to those placed in normal lab water. ... of colon cancer cells 62.5 percent more quickly than normal ...
Cached Medicine News:Health News:India’s Silent Killer on the Prow 2Health News:17 percent rise in childhood cancer cases due to modern lifestyles 2
CTAD tubes contain theophylline, adenosine and dipyridamol. Coagulation and DTAD tubes are for examination of coagulation parameters....
... tubes contain a buffered sodium ... with a citrate concentration of ... mol/l (3.8%). The mixing ratio ... to 9 parts blood. In ...
Inquire...
Inquire...
Medicine Products: